Treatment of patients with AML with approved FLT3 inhibitors (gilteritinib, quizartinib, midostaurin, and sorafenib), IDH inhibitors, the BCL2 inhibitor venetoclax (VEN), chemotherapeutics, and hypomethylating agents is linked to a myriad of resistance mutations, and no drug has been developed with a broad range of activity and safety across patients with AML with a diversity of adverse mutations (4–10). Here, FLT3 is linked to acute myeloid leukemia.